JUNE 2026 AGM RECORDING
C.E.O. & Board of Directors
Emily Jameson is a finance executive with over a decade of experience in investment banking, private equity, and corporate development. She currently serves as Director, Corporate Development, Banking and Strategy at Independent Trading Group, where she is responsible for capital raising, mergers and acquisitions, and long-term strategic planning for small and mid-capitalization companies.
Previously, Ms. Jameson worked in private equity at Novacap in the Technology, Media and Telecommunications group, where she focused on transaction sourcing, due diligence, and execution, and served as a board observer for an industrial technology portfolio company.
Prior to that, she was Vice President, Investment Banking at Canaccord Genuity, where she sourced and executed investments for the firm’s Fintech Fund and led a range of public and private financings, including several notable transactions in the cannabis sector. Ms. Jameson holds a Bachelor of Business Administration from Memorial University and a Master of Business Administration from Saint Mary’s University. Ms. Jameson is passionate about fostering innovation and driving sustainable growth.
Emily Jameson is a finance executive with over a decade of experience in investment banking, private equity, and corporate development. She currently serves as Director, Corporate Development, Banking and Strategy at Independent Trading Group, where she is responsible for capital raising, mergers and acquisitions, and long-term strategic planning for small and mid-capitalization companies.
Previously, Ms. Jameson worked in private equity at Novacap in the Technology, Media and Telecommunications group, where she focused on transaction sourcing, due diligence, and execution, and served as a board observer for an industrial technology portfolio company.
Prior to that, she was Vice President, Investment Banking at Canaccord Genuity, where she sourced and executed investments for the firm’s Fintech Fund and led a range of public and private financings, including several notable transactions in the cannabis sector. Ms. Jameson holds a Bachelor of Business Administration from Memorial University and a Master of Business Administration from Saint Mary’s University. Ms. Jameson is passionate about fostering innovation and driving sustainable growth.
David Pidduck joined MediPharm Labs with over 20 years experience in the Canadian and international pharmaceutical industries. David has a wealth of experience in driving strategic change in complex and ambiguous environments. His previous roles within the pharmaceutical industry have centred around transformation, portfolio and channel diversification, and he’s been recognized for driving significant revenue and profit growth during his tenures. David prides himself in being a people-centric leader who has been able to increase employee engagement while transforming multi-national organizations.
David holds an EMBA from the Kellogg School of Business at Northwestern University, and an Honors BBA from Wilfred Laurier University.
David Pidduck joined MediPharm Labs with over 20 years experience in the Canadian and international pharmaceutical industries. David has a wealth of experience in driving strategic change in complex and ambiguous environments. His previous roles within the pharmaceutical industry have centred around transformation, portfolio and channel diversification, and he’s been recognized for driving significant revenue and profit growth during his tenures. David prides himself in being a people-centric leader who has been able to increase employee engagement while transforming multi-national organizations.
David holds an EMBA from the Kellogg School of Business at Northwestern University, and an Honors BBA from Wilfred Laurier University.
Keith Strachan is the CEO of BioFlight Fuels, a renewable energy company creating sustainable aviation fuel from waste.
Keith is a co-founder of MediPharm Labs and served as President from 2017 to 2025. A seasoned entrepreneur, Keith applied his leadership to building out MediPharm Labs’ leading-edge facilities, while also strategically driving business development with the company’s customers in Canada, Australia, South America, and the European Union. Prior to entrepreneurism, Keith held various public service roles with the Ontario Government and Royal Victoria Regional Health Centre, focused primarily on supply chain management. Appointed by the Ontario Attorney General, Keith currently sits as a member of the Ontario Judicial Appointments Advisory Committee. As a resident of Barrie, he is an active community contributor, including a member of the Kempenfelt Rotary Club.
Keith Strachan is the CEO of BioFlight Fuels, a renewable energy company creating sustainable aviation fuel from waste.
Keith is a co-founder of MediPharm Labs and served as President from 2017 to 2025. A seasoned entrepreneur, Keith applied his leadership to building out MediPharm Labs’ leading-edge facilities, while also strategically driving business development with the company’s customers in Canada, Australia, South America, and the European Union. Prior to entrepreneurism, Keith held various public service roles with the Ontario Government and Royal Victoria Regional Health Centre, focused primarily on supply chain management. Appointed by the Ontario Attorney General, Keith currently sits as a member of the Ontario Judicial Appointments Advisory Committee. As a resident of Barrie, he is an active community contributor, including a member of the Kempenfelt Rotary Club.
John Medland is the Head of Advisory at Paradigm Capital Inc. advising public and private clients on M&A, restructuring and governance matters. John has over 20 years of experience advising on capital markets strategy. Throughout his career, he has led a broad range of corporate advisory engagements, including divestitures, acquisitions, valuations, restructurings, and unsolicited bid mandates. His expertise also extends to public and private capital raising transactions, including initial public offerings, bought deals, convertible securities, and debt financings.
John’s client base spans a diverse range of industry sectors including mining, Technology, Media and Telecommunications (TMT), financial services and healthcare. Before joining Paradigm, John led Scotiabank’s Canadian Technology business, providing strategic financial guidance to clients across the sector. John started his career in the Mergers and Acquisitions group at RBC Capital Markets and was a partner at Blair Franklin Capital Partners.
John holds a Bachelor of Commerce degree from Queen's University (First Class Honours) and is a Chartered Financial Analyst (CFA). He serves as a Board Member and Chair of the Finance Committee for Amici Children's Camp Charity. He is also a past Board Member of Canadian Club Toronto and the Upper Canada College Association Council.
John Medland is the Head of Advisory at Paradigm Capital Inc. advising public and private clients on M&A, restructuring and governance matters. John has over 20 years of experience advising on capital markets strategy. Throughout his career, he has led a broad range of corporate advisory engagements, including divestitures, acquisitions, valuations, restructurings, and unsolicited bid mandates. His expertise also extends to public and private capital raising transactions, including initial public offerings, bought deals, convertible securities, and debt financings.
John’s client base spans a diverse range of industry sectors including mining, Technology, Media and Telecommunications (TMT), financial services and healthcare. Before joining Paradigm, John led Scotiabank’s Canadian Technology business, providing strategic financial guidance to clients across the sector. John started his career in the Mergers and Acquisitions group at RBC Capital Markets and was a partner at Blair Franklin Capital Partners.
John holds a Bachelor of Commerce degree from Queen's University (First Class Honours) and is a Chartered Financial Analyst (CFA). He serves as a Board Member and Chair of the Finance Committee for Amici Children's Camp Charity. He is also a past Board Member of Canadian Club Toronto and the Upper Canada College Association Council.
Michael served as the Chief Financial Officer of VIVO for over 5 years prior to MediPharm Labs acquiring VIVO Cannabis. Michael has over 20 years of experience in pharmaceuticals with more than 10 years spent internationally with Eli Lilly. He has held previous CFO roles with multiple, NASDAQ and TSX listed public Canadian biotech companies.
Michael served as the Chief Financial Officer of VIVO for over 5 years prior to MediPharm Labs acquiring VIVO Cannabis. Michael has over 20 years of experience in pharmaceuticals with more than 10 years spent internationally with Eli Lilly. He has held previous CFO roles with multiple, NASDAQ and TSX listed public Canadian biotech companies.
Greg Hunter joined MediPharm Labs as Chief Financial Officer in 2021 and was appointed Interim Chief Executive Officer in January 2026. During his MediPharm tenure, he has led significant cost‑reduction initiatives and strengthened financial and operational controls, while also advancing commercial performance. With over 20 years of leadership experience at global organizations including Johnson & Johnson and Baxter, he brings deep financial, operational, and commercial expertise to the company. Greg is recognized for his cross‑functional leadership and his ability to drive disciplined execution and strong commercial performance.
Greg Hunter joined MediPharm Labs as Chief Financial Officer in 2021 and was appointed Interim Chief Executive Officer in January 2026. During his MediPharm tenure, he has led significant cost‑reduction initiatives and strengthened financial and operational controls, while also advancing commercial performance. With over 20 years of leadership experience at global organizations including Johnson & Johnson and Baxter, he brings deep financial, operational, and commercial expertise to the company. Greg is recognized for his cross‑functional leadership and his ability to drive disciplined execution and strong commercial performance.
Stock Data
Stock Quote
Medipharm Labs Corp
Toronto Stock Exchange: LABS:CA
Detailed Information
Stock Quote
Medipharm Labs Corp
OTCQB Marketplace: MEDIF:US
Detailed Information
Stock Quote
Medipharm Labs Corp
Berlin: MLZ:BE
Detailed Information
Firm
Analysts
All analyst coverage is conducted by third parties. Please note that any opinions, estimates or forecasts regarding MediPharm Labs' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of MediPharm Labs or its management. MediPharm Labs does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. As such the content of any analyst coverage should not be considered financial advice or forecasting that is approved or endorsed by MediPharm Labs.
Sedar
Corporate Governance
The Board of Directors of MediPharm Labs Corp. (the “Company”) sets high standards for the Company’s service providers, employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
and Nomination